Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALUR Allurion Technologies	$2.46 -0.8%	$2.57	$2.15 ▼ $88.75	$18.35M	-0.47	788,676 shs	55,935 shs
GEVO Gevo	$1.38 +7.8%	$1.15	$0.48 ▼ $3.39	$330.60M	2.53	5.46 million shs	4.09 million shs
KULR KULR Technology Group	$0.90 -22.0%	$1.26	$0.20 ▼ $5.49	$245.27M	2.34	15.64 million shs	90.53 million shs
LUCD Lucid Diagnostics	$1.26 -2.3%	$1.30	$0.68 ▼ $1.80	$136.32M	1.31	586,755 shs	753,191 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALUR Allurion Technologies	0.00%	-7.78%	-21.45%	-3.45%	-91.90%
GEVO Gevo	0.00%	+10.34%	+4.92%	-9.86%	+120.80%
KULR KULR Technology Group	0.00%	-2.54%	-10.16%	-34.66%	+215.59%
LUCD Lucid Diagnostics	0.00%	0.00%	+2.38%	-12.24%	+72.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALUR Allurion Technologies	3.3331 of 5 stars	3.5	4.0	2.2	3.3	0.6
GEVO Gevo	2.2567 of 5 stars	3.3	2.0	2.5	0.8	1.3
KULR KULR Technology Group	1.9313 of 5 stars	3.5	2.0	1.8	0.8	0.6
LUCD Lucid Diagnostics	3.5574 of 5 stars	3.6	5.0	3.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALUR Allurion Technologies	3.00	Buy	$22.83	828.18% Upside
GEVO Gevo	2.50	Moderate Buy	$7.58	448.91% Upside
KULR KULR Technology Group	3.00	Buy	$5.00	457.66% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.55	181.75% Upside

Current Analyst Ratings Breakdown

Latest ALUR, LUCD, KULR, and GEVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
5/30/2025	GEVO Gevo	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/2/2025	GEVO Gevo	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.25 ➝ $1.15
3/28/2025	GEVO Gevo	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/27/2025	ALUR Allurion Technologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.50 ➝ $2.50
3/26/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
3/25/2025	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALUR Allurion Technologies	$28.30M	0.65	N/A	N/A	($36.95) per share	-0.07
GEVO Gevo	$42.03M	7.86	N/A	N/A	$2.32 per share	0.59
KULR KULR Technology Group	$9.83M	24.95	N/A	N/A	($0.02) per share	-44.83
LUCD Lucid Diagnostics	$4.17M	32.67	N/A	N/A	($0.47) per share	-2.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALUR Allurion Technologies	-$80.61M	-$12.50	N/A	N/A	N/A	-71.24%	N/A	-56.75%	8/12/2025 (Estimated)
GEVO Gevo	-$66.21M	-$0.36	N/A	N/A	N/A	-510.04%	-14.95%	-12.69%	8/6/2025 (Estimated)
KULR KULR Technology Group	-$23.69M	-$0.12	N/A	N/A	N/A	-186.55%	-751.30%	-157.66%	8/11/2025 (Estimated)
LUCD Lucid Diagnostics	-$52.67M	-$1.34	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	8/11/2025 (Estimated)

Latest ALUR, LUCD, KULR, and GEVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ALUR Allurion Technologies	-$1.53	$0.43	+$1.96	$0.20	$5.50 million	$5.58 million
5/13/2025	Q1 2025	GEVO Gevo	-$0.10	-$0.09	+$0.01	-$0.09	$22.19 million	$29.11 million
3/27/2025	Q4 2024	GEVO Gevo	-$0.11	-$0.09	+$0.02	-$0.09	$3.85 million	$4.15 million
3/26/2025	Q4 2024	ALUR Allurion Technologies	-$5.00	-$7.00	-$2.00	-$7.95	$5.60 million	$5.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALUR Allurion Technologies	N/A	N/A	N/A	N/A	N/A
GEVO Gevo	N/A	N/A	N/A	N/A	N/A
KULR KULR Technology Group	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALUR Allurion Technologies	N/A	2.33	2.09
GEVO Gevo	0.13	8.25	8.05
KULR KULR Technology Group	0.05	0.81	0.71
LUCD Lucid Diagnostics	N/A	1.18	1.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALUR Allurion Technologies	21.39%
GEVO Gevo	35.17%
KULR KULR Technology Group	21.23%
LUCD Lucid Diagnostics	74.01%

Insider Ownership

Company	Insider Ownership
ALUR Allurion Technologies	22.40%
GEVO Gevo	6.80%
KULR KULR Technology Group	11.21%
LUCD Lucid Diagnostics	6.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALUR Allurion Technologies	501	7.46 million	2.01 million	Optionable
GEVO Gevo	100	239.56 million	229.83 million	Optionable
KULR KULR Technology Group	60	273.55 million	242.89 million	Not Optionable
LUCD Lucid Diagnostics	70	108.19 million	54.12 million	No Data

ALUR, LUCD, KULR, and GEVO Headlines

Recent News About These Companies

Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 39.3% in May

June 16 at 3:51 PM | marketbeat.com

Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus Rating of "Buy" by Brokerages

June 16 at 3:08 AM | marketbeat.com

Lucid Diagnostics (NASDAQ:LUCD) Price Target Raised to $7.75 at Ascendiant Capital Markets

June 8, 2025 | americanbankingnews.com

Ascendiant Capital Markets Forecasts Strong Price Appreciation for Lucid Diagnostics (NASDAQ:LUCD) Stock

June 6, 2025 | marketbeat.com

Lucid Diagnostics Inc. (NASDAQ:LUCD) Sees Large Increase in Short Interest

June 3, 2025 | marketbeat.com

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

May 27, 2025 | prnewswire.com

Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Buy" from Analysts

May 24, 2025 | marketbeat.com

Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential

May 21, 2025 | investing.com

Lucid Diagnostics Reports Increased Losses Amid Revenue Decline

May 16, 2025 | tipranks.com

Earnings call transcript: Lucid Diagnostics Q1 2025 highlights growth and strategic expansion

May 15, 2025 | investing.com

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

May 15, 2025 | prnewswire.com

Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript

May 14, 2025 | seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates

May 14, 2025 | zacks.com

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

May 14, 2025 | prnewswire.com

Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know

May 7, 2025 | zacks.com

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

April 30, 2025 | prnewswire.com

Lucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in study

April 26, 2025 | markets.businessinsider.com

Lucid Diagnostics Reports Positive Data for EsoGuard in Study of Asymptomatic Patients

April 24, 2025 | theglobeandmail.com

Lucid reports encouraging results from EsoGuard study

April 24, 2025 | msn.com

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

April 24, 2025 | prnewswire.com

Lucid Diagnostics price target raised to $7.50 from $7 at Ascendiant

April 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR, LUCD, KULR, and GEVO Company Descriptions

Allurion Technologies NYSE:ALUR

$2.46 -0.02 (-0.81%)

Closing price 03:58 PM Eastern

Extended Trading

$2.50 +0.04 (+1.83%)

As of 06:51 PM Eastern

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Gevo NASDAQ:GEVO

$1.38 +0.10 (+7.81%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 -0.02 (-1.81%)

As of 07:06 PM Eastern

Gevo, Inc. operates as a carbon abatement company. It operates through three segments: Gevo, Agri-Energy, and Renewable Natural Gas. The company focuses on transforming renewable energy into energy-dense liquid hydrocarbons that can be used as renewable fuels. It offers renewable gasoline and diesel, isobutanol, sustainable aviation fuel, renewable natural gas, isobutylene, ethanol, and animal feed and protein. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was incorporated in 2005 and is headquartered in Englewood, Colorado.

KULR Technology Group NYSEAMERICAN:KULR

$0.90 -0.25 (-22.03%)

Closing price 04:10 PM Eastern

Extended Trading

$0.88 -0.02 (-1.96%)

As of 07:25 PM Eastern

KULR Technology Group, Inc., through its subsidiary, KULR Technology Corporation, develops and commercializes thermal management technologies for electronics, batteries, and other components applications in the United States. It provides lithium-ion battery thermal runaway shields; automated battery cell screening and test systems; cellchecks; safecases; fiber thermal interface materials; phase change material heat sinks; internal short circuit devices; and CRUX cathodes. The company's technologies are used in electric vehicles, energy storage, battery recycling transportation, cloud computing, and 5G communication devices. It sells its products for applications, such as lithium-ion battery energy storage, electric vehicles, 5G communication, cloud computer infrastructure, consumer, and industrial devices. The company was formerly known as KT High-Tech Marketing Inc. and changed its name to KULR Technology Group, Inc. in August 2018. KULR Technology Group, Inc. was founded in 2013 and is based in San Diego, California.

Lucid Diagnostics NASDAQ:LUCD

$1.26 -0.03 (-2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 +0.00 (+0.40%)

As of 07:22 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time